Sanofi (SNY) announces Libtayo approved for advanced cutaneous squamous cell carcinoma in European Union

July 1, 2019 10:02 AM
The European Commission (EC) has granted conditional marketing authorization for Libtayo® (cemiplimab) for the treatment of adults with metastatic or ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles